|
Apricoxib (TG01, CS-706)
Capoxigem®- Oncology
Cancer is driven by abnormalities in a number of normal
cell processes, mediated by signaling pathways, such as COX-2.
Abnormalities in these pathways leading to oncogenic transformation
include the HIF-1, VEGF, VEGF-R and PDGF systems for angiogenesis;
the EGFR, HER2/neu, Bcr/Abl for growth control and differentiation;
the intrinsic and extrinsic pathways for apoptosis; the integrin
and metalloproteinase systems for tissue invasion and metastasis.
Further, multiple pathways are often deregulated in cancer
cells due to the inherent genetic instability of these cells.
Effective treatments for cancer will address these oncogenic
signaling pathways as well as the redundancy of survival signals
present in cancer cells.
Tragara has identified a biomarker which identifies patients
who are most likely to benefit from Capoxigem therapy. Tragara
is selecting patients in its Phase II lung cancer program
using the biomarker and intends to develop ProGEM as the diagnostic
kit for biomarker detection.
Kymena®- Inflammation
Inflammation lies at the heart of many disease states, including cancer, joint
disease, skin disease, asthma, intestinal disease, and autoimmune
disease. An unchecked inflammatory response can destroy tissues,
cause pain and inhibit the natural function of many tissues
and organs. Capoxigem and other COX-2 inhibitors mediate inflammation
through the tumor necrosis family (TNF), neutrophil contents,
the CXCR family, and cytokines such as IL-6 and IL-10.
In the Inflammation program, Capoxigem is being evaluated
as an oral anti-inflammatory agent. In pre-clinical animal
models of inflammation, Capoxigem was superior to currently-marketed
inflammation therapies. A Phase IIa clinical study in inflammation/pain
has been completed and Kymena demonstrated superior painrelief
to both placebo and active comparators. The compound is oral,
well tolerated, and anticipated to be dosed once daily.
|
